PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
AboutPricing
Drug ReportsOxaliplatin
Oxaliplatin
Oxaliplatin (oxaliplatin) is a small molecule pharmaceutical. Oxaliplatin was first approved as Eloxatin on 2002-08-09. It is used to treat colorectal neoplasms, ovarian neoplasms, testicular neoplasms, and urinary bladder neoplasms in the USA.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
neoplasmsD009369
digestive system diseasesD004066
urogenital diseasesD000091642
endocrine system diseasesD004700
Trade Name
FDA
EMA
Oxaliplatin (discontinued: Eloxatin, Oxaliplatin)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Oxaliplatin
Tradename
Company
Number
Date
Products
OXALIPLATINTevaN-022160 RX2009-08-07
2 products, RLD, RS
Show 2 discontinued
Labels
FDA
EMA
Brand Name
Status
Last Update
oxaliplatinANDA2025-02-24
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
L: Antineoplastic and immunomodulating agents
L01: Antineoplastic agents
L01X: Other antineoplastic agents in atc
L01XA: Platinum compounds, antineoplastic drugs
L01XA03: Oxaliplatin
HCPCS
Code
Description
J9263
Injection, oxaliplatin, 0.5 mg
Clinical
Clinical Trials
3022 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Colorectal neoplasmsD015179725191349
Colonic neoplasmsD003110C18111115
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
AdenocarcinomaD000230216118
Rectal neoplasmsD012004312215
Esophageal neoplasmsD004938C1518210
Head and neck neoplasmsD00625877
Breast neoplasmsD001943EFO_0003869C5066
Biliary tract neoplasmsD001661C24.955
Gallbladder neoplasmsD005706EFO_0004606C23144
Ovarian neoplasmsD010051EFO_0003893C56123
Urinary bladder neoplasmsD001749C67133
Squamous cell carcinomaD00229433
Show 35 more
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Peritoneal neoplasmsD01053411
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
HypersensitivityD006967EFO_0003785T78.4011
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameOxaliplatin
INNoxaliplatin
Description
Oxaliplatin, sold under the brand name Eloxatin among others, is a cancer medication (platinum-based antineoplastic class) used to treat colorectal cancer. It is given by injection into a vein.
Classification
Small molecule
Drug classantineoplastics (platinum derivatives)
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
Identifiers
PDB
CAS-ID61825-94-3
RxCUI
ChEMBL IDCHEMBL414804
ChEBI ID
PubChem CID11947679
DrugBankDB00526
UNII ID04ZR38536J (ChemIDplus, GSRS)
Target
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 68,524 documents
View more details
Safety
Black-box Warning
Black-box warning for: Oxaliplatin
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
74,125 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use